<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029037</url>
  </required_header>
  <id_info>
    <org_study_id>DAVCI</org_study_id>
    <nct_id>NCT05029037</nct_id>
  </id_info>
  <brief_title>High-dose Intravenous Vitamin C (HDIVC) as Adjuvant Therapy in Critical Patients With Positive COVID-19. A Pilot Randomized Controlled Dose-comparison Trial.</brief_title>
  <acronym>HDIVC</acronym>
  <official_title>High-dose Intravenous Vitamin C (HDIVC) as Adjuvant Therapy in Critical Patients With Positive COVID-19. A Pilot Randomized Controlled Dose-comparison Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo Galindo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Epheta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the impact of this HDIVC therapy in the first&#xD;
      treatment of symptomatic Covid-19 patients in a time period of one week.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We consider that treatment with high doses of injectable vitamin C HDIVC could have a&#xD;
      positive impact as an adjunct on the immunity of patients with Covid while reducing the&#xD;
      possibility of worsening their clinical picture. Similarly, we wish to evaluate the efficacy&#xD;
      of this treatment, for one week, in patients hospitalized in the ICU, in order to reduce the&#xD;
      inflammatory burden and reduce hospital stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in worst (highest)</measure>
    <time_frame>Seven (7) days after randomization.</time_frame>
    <description>Mean change in worst (highest) oxygenation level (oxygen saturation or oxygen flow in liters/min) in non-ventilated patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in worst (lowest)</measure>
    <time_frame>Seven (7) days after randomization.</time_frame>
    <description>Mean change in worst (lowest) PaO2 / FiO2 ratio (in mmHg) in ventilated patients. It should be within the first seven days after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to day 28</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Days</time_frame>
    <description>Duration of mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients randomized to group A will receive two doses (High) of vitamin C intravenously, twice a day for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>80 patients assigned to group B will receive two doses of Dextrose 500 mL, twice a day for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High doses of intravenous vitamin C</intervention_name>
    <description>Two (2) High doses of intravenous vitamin C for seven (7) days.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose 500 mL</intervention_name>
    <description>Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.&#xD;
Twice a day for seven days.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with consent, adult men or women, age ≥ 18 years.&#xD;
&#xD;
          -  Laboratory confirmed SARS-CoV-2 infection as determined by polymerase chain reaction&#xD;
             (PCR) or other commercial or public health assays; and/or clinical findings suggesting&#xD;
             infection.&#xD;
&#xD;
          -  Hospitalized with a SARS-CoV-2 infection of any duration.&#xD;
&#xD;
          -  Ability to provide an informed consent signed by the study patient or a legally&#xD;
             acceptable representative.&#xD;
&#xD;
          -  Willingness and ability to comply with the procedures/evaluations related to the&#xD;
             study.&#xD;
&#xD;
          -  Have an oxygen saturation (SaO2) of 94% or less while breathing room air; or a ratio&#xD;
             between the partial pressure of oxygen (PaO2) and the fraction of inspired oxygen&#xD;
             (FiO2) (Pao2: Fio2) equal to or less than 300 mg. Hg. (WHO defines PAFI less than or&#xD;
             equal to 250; being mild: 200-300; moderate: 100-200; severe: 100 or less.&#xD;
&#xD;
          -  Normal kidney function: (creatinine 0.7 mg / dl for men or 20 to 200ng / ml and 0.6 to&#xD;
             1.1 mg / dl for women or 15-150 ng / ml); urinary output greater than or equal to 1 cc&#xD;
             / kg / hour; glomerular filtration rate greater than 30 cc / min).&#xD;
&#xD;
          -  Without chronic kidney disease (CKD) defined by stage II or higher according to the&#xD;
             Kidney Disease Improving Global Outcomes (KDIGO) classification.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or pregnant or lactating woman.&#xD;
&#xD;
          -  Allergy to vitamin C.&#xD;
&#xD;
          -  Severe liver failure.&#xD;
&#xD;
          -  eGFR ≤ 30 ml / min / 1.73 m2 (defined by the CKD-EPI SCr formula).&#xD;
&#xD;
          -  History of any organ transplants requiring treatment active immunosuppressant that may&#xD;
             interfere with kidney function.&#xD;
&#xD;
          -  If you required cardiopulmonary resuscitation (CPR) within 14 days, and/or DNR orders&#xD;
             (do not resuscitate) DNI (do not intubate).&#xD;
&#xD;
          -  If death is considered imminent or unavoidable during this admission, and the treating&#xD;
             physician, patient, or surrogate decision-maker is not engaged in active treatment.&#xD;
&#xD;
          -  Be on dialysis (either acute or chronic) or need dialysis imminent at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients with known HIV infection.&#xD;
&#xD;
          -  Patients with a known or suspected history of nephropathy due to oxalate or&#xD;
             hyperoxaluria, scurvy, chronic iron overload, deficiency by G-6PD.&#xD;
&#xD;
          -  Patients with known hemochromatosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hugo Galindo, MD</last_name>
    <phone>57 3006292776</phone>
    <email>hgalindo@grupogales.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Epheta</investigator_affiliation>
    <investigator_full_name>Hugo Galindo</investigator_full_name>
    <investigator_title>Dr. Hugo Galindo</investigator_title>
  </responsible_party>
  <keyword>Vitamin C- Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

